
    
      This is a multi-centre, observational cohort study of EU hemodialysis patients whose
      erythropoiesis stimulating agent (ESA) therapy has been switched from PEG epoetin beta to
      darbepoetin alfa. Data will be collected for the period spanning 14 weeks prior to switch
      through to 26 weeks post-switch.
    
  